Evidence map›Paper›PMID 26466668›Full record

ArticleBMC cancer2015

Development of novel real-time PCR methodology for quantification of COL11A1 mRNA variants and evaluation in breast cancer tissue specimens.

Makrina Karaglani, Ioannis Toumpoulis, Nikolaos Goutas, Nikoleta Poumpouridou, Dimitrios Vlachodimitropoulos, Spyridon Vasilaros, Ioannis Rizos, Christos Kroupis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. COL11A1 is Downregulated by miR-339-5p and Promotes Colon Carcinoma Progression.Canadian journal of gastroenterology & hepatology · 2022
    Article
  4. Article
  5. Article
  6. Cancer management and research · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Makrina KaraglaniDepartment of Clinical Biochemistry and Molecular Diagnostics, Attikon University General Hospital, University of Athens Medical School, Rimini 1 St., Haidari, 12462, Greece. makrina.karaglani@gmail.com.
Ioannis ToumpoulisDepartment of Cardiothoracic Surgery, Attikon University General Hospital, University of Athens Medical School, Athens, Greece. itoumpoulis@med.uoa.gr.
Nikolaos GoutasPathologic Anatomy Laboratory, Evgenidio Hospital, University of Athens Medical School, Athens, Greece. ngoutas@med.uoa.com.
Nikoleta PoumpouridouDepartment of Clinical Biochemistry and Molecular Diagnostics, Attikon University General Hospital, University of Athens Medical School, Rimini 1 St., Haidari, 12462, Greece. poumpouridounikoleta@gmail.com.
Dimitrios VlachodimitropoulosPathologic Anatomy Laboratory, Evgenidio Hospital, University of Athens Medical School, Athens, Greece. dvlacho@med.uoa.gr.
Spyridon VasilarosProlipsis Breast Cancer Clinic, Athens, Greece. xkro48@otenet.gr.
Ioannis RizosDepartment of Cardiology, Attikon University General Hospital, University of Athens Medical School, Athens, Greece. irizos@med.uoa.gr.
Christos KroupisDepartment of Clinical Biochemistry and Molecular Diagnostics, Attikon University General Hospital, University of Athens Medical School, Rimini 1 St., Haidari, 12462, Greece. ckroupis@med.uoa.gr.
National and Kapodistrian University of Athens · GRUniversity General Hospital Attikon · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCollagen XI is a key structural component of the extracellular matrix and consists of three alpha chains. One of these chains, the α1 (XI), is encoded by the COL11A1 gene and is transcribed to four different variants at least (A, B, C and E) that differ in the propensity to N-terminal domain proteolysis and potentially in the way the extracellular matrix is arranged. This could affect the ability of tumor cells to invade the remodeled stroma and metastasize. No study in the literature has so far investigated the expression of these four variants in breast cancer nor does a method for their accurate quantitative detection exist.

methodsWe developed a conventional PCR for the general detection of the general COL11A1 transcript and real-time qPCR methodologies with dual hybridization probes in the LightCycler platform for the quantitative determination of the variants. Data from 90 breast cancer tissues with known histopathological features were collected.

resultsThe general COL11A1 transcript was detected in all samples. The developed methodologies for each variant were rapid as well as reproducible, sensitive and specific. Variant A was detected in 30 samples (33 %) and variant E in 62 samples (69 %). Variants B and C were not detected at all. A statistically significant correlation was observed between the presence of variant E and lymph nodes involvement (p = 0.037) and metastasis (p = 0.041).

conclusionsWith the newly developed tools, the possibility of inclusion of COL11A1 variants as prognostic biomarkers in emerging multiparameter technologies examining tissue RNA expression should be further explored.

Indexed as

Genetic VariationReal-Time Polymerase Chain ReactionAdultAgedAlternative SplicingBiomarkers, TumorBreast NeoplasmsCollagen Type XIFemaleGene ExpressionHumansKaplan-Meier EstimateMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingBiomarkers, TumorCOL11A1 protein, humanCollagen Type XIRNA, Messenger

Identifiers

PMID26466668
PMCPMC4606509
OpenAlexW1913948307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.